Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2003 October;138(5) > Giornale Italiano di Dermatologia e Venereologia 2003 October;138(5):349-54

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

REVIEWS  


Giornale Italiano di Dermatologia e Venereologia 2003 October;138(5):349-54

language: English

Advances in immunotherapy for psoriasis

Young H. S., Griffiths C. E. M.

Dermatopharmacology Unit, The Dermatology Centre University of Manchester, Hope Hospital, Manchester, UK


PDF  


Over the past 20 years it has become accepted that psoriasis is a T-cell-mediated, probably autoimmune disease. Initial observations that ciclosporin is an effective therapy for psoriasis helped substantiate the T-cell-mediated hypothesis. The development of new selective targeted immunotherapies for psoriasis have not only provided new therapies but in addition have helped dissect the key pathways in this disease. The new biological therapies fall into 2 categories – T cell targeting and cytokine modulation. Examples of the former include an LFA-3 fusion protein (alefacept) and anti-CD11a (efalizamab). Cytokine modulation includes: inhibition of proinflammatory cytokines such as tumour necrosis factor-a e.g. infliximab and etanercept; and cytokine switching by administration of Th2 cytokines such as interleukin-10. The introduction of biological therapies will undoubtedly broaden our armamentarium for psoriasis treatment and perhaps, with their specificity of action, may allow identification of disease subsets.

top of page

Publication History

Cite this article as

Corresponding author e-mail